Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesAlliance Pharma plc

Alliance Pharma plc

Healthcare Drug Manufacturers - Specialty & Generic
PortfolioPortfolio WatchlistWatchlist
Company price
None GBX 0.00(0%)
Last update at 2025-06-13T16:00:04.809529Z
Market Cap
212.37M

Momentum Score

…

Alliance Pharma plc operates as a pharmaceutical company in Europe, the Middle East, Africa, the Asia Pacific, China, and the Americas. The company acquires, markets, and distributes consumer healthcare and prescription medicine products. The company also offers medicines, medical devices, food supplements, and cosmetics. It provides its products under the Aloclair, Anbesol, Asthon and Parsons, Forceval, Hydromol, Kelo-cote, Macushield, Vamousse, Nizoral, and Amberen brand names. Alliance Pharma plc was incorporated in 1996 and is headquartered in Chippenham, the United Kingdom.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
33.70
Low
71.45
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
64.70
Dividend Yield
3.75%
Revenue TTM
167.42M
Revenue Per Share
0.31
Gross Profit TTM
101.68M
Debt / Equity
0.46
ROE
0.33%
Net Debt
102.03M
ROCE
2.16%
Diluted EPS TTM
-0.01

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 5.21M 18.16M 13.02M 31.08M 22.80M
Net income 0.94M 7.32M 8.03M 25.01M 18.36M
Selling general administrative 63.59M 63.05M 45.91M 46.81M 41.93M
Gross profit 101.68M 109.45M 82.82M 86.08M 72.65M
Reconciled depreciation 10.76M 16.25M 20.96M 1.96M 7.79M
Ebit 10.57M 21.57M 27.15M 35.63M 25.84M
Ebitda 20.75M 43.57M 48.11M 38.14M 33.63M
Depreciation and amortization 10.18M 21.99M 20.96M 2.51M 7.79M
Operating income 10.57M 21.57M 27.15M 35.63M 28.92M
Other operating expenses 138.61M 135.48M 101.43M 98.19M 89.28M
Interest expense 4.79M 3.01M 2.08M 3.29M 3.04M
Tax provision 4.27M 10.84M 4.99M 6.07M 4.45M
Interest income 0.02M 0.02M 0.01M 0.02M 0.05M
Net interest income -5.42M -3.62M -2.65M -3.75M -1.44M
Income tax expense 4.27M 10.84M 4.99M 6.07M 4.45M
Total revenue 167.42M 163.21M 129.80M 135.64M 118.21M
Total operating expenses 72.88M 81.72M 54.44M 48.63M 43.72M
Cost of revenue 65.73M 53.76M 46.98M 49.56M 45.56M
Total other income expense net -5.36M -3.42M -14.13M -4.55M -6.12M
Net income from continuing ops 0.94M 7.32M 8.03M 25.01M 18.36M
Net income applicable to common shares 0.94M 7.32M 8.03M 25.01M 18.36M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 537.41M 503.49M 508.85M 407.64M 403.61M
Intangible assets 400.10M 382.51M 381.61M 312.13M 318.68M
Other current assets 0.16M 30.89M 25.42M 31.69M 29.15M
Total liab 249.75M 221.00M 227.90M 133.46M 151.41M
Total stockholder equity 287.66M 282.49M 280.96M 274.18M 252.20M
Deferred long term liab - - - - 0.77M
Other current liab 10.79M 10.19M 17.95M 16.21M 11.00M
Common stock 5.40M 5.38M 5.33M 5.29M 5.18M
Capital stock 5.40M 5.38M 5.33M 5.29M 5.18M
Retained earnings 108.24M 116.42M 117.70M 112.51M 95.10M
Other liab - 61.73M 56.65M 30.21M 29.04M
Good will 21.53M 31.24M 31.26M 16.53M 16.57M
Other assets 4.72M 3.90M 2.82M 2.39M 2.79M
Cash 31.71M 29.06M 28.90M 17.83M 10.89M
Total current liabilities 47.02M 40.58M 30.19M 24.21M 91.72M
Net debt 102.03M 87.00M 113.12M 62.23M 88.23M
Short term debt 0.61M 0.46M 0.96M 1.02M 68.48M
Short long term debt - - - 0.00M 68.03M
Short long term debt total 133.74M 116.06M 142.02M 80.06M 99.12M
Other stockholder equity 174.02M 160.69M 157.93M 156.37M 155.66M
Property plant equipment - 4.83M 4.49M 4.21M 3.34M
Total current assets 105.48M 81.02M 77.24M 65.04M 58.75M
Net tangible assets - -131.26M -143.34M -61.82M -86.53M
Net receivables 49.32M 30.82M 24.22M 30.29M 27.93M
Long term debt 133.74M 116.06M 138.33M 77.04M 28.67M
Inventory 24.29M 21.07M 22.92M 15.52M 18.71M
Accounts payable 35.62M 29.93M 11.28M 6.97M 8.98M
Accumulated other comprehensive income - - - -4.96M -3.75M
Common stock total equity - - 5.33M 5.29M 5.18M
Non currrent assets other 0.60M 0.37M 0.68M 0.68M 0.18M
Non current assets total 431.93M 422.47M 431.61M 342.60M 344.86M
Capital lease obligations 3.83M 2.88M 3.69M 3.02M 2.42M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -17.02M -4.60M -85.86M 0.50M 2.20M
Change to liabilities 7.28M -0.33M 5.93M -3.80M 5.06M
Total cashflows from investing activities -17.02M -4.60M -85.86M -3.28M -59.08M
Net borrowings 12.70M -23.51M 60.17M -18.20M 11.68M
Total cash from financing activities -0.88M -34.34M 55.75M -25.20M 36.59M
Change to operating activities -1.08M 9.47M 9.47M 9.47M -0.01M
Net income 0.94M 7.32M 8.03M 25.01M 18.36M
Change in cash 2.65M 0.16M 11.07M 6.94M -0.29M
Begin period cash flow 29.06M 28.90M 17.83M 10.89M 11.18M
End period cash flow 31.71M 29.06M 28.90M 17.83M 10.89M
Total cash from operating activities 20.97M 38.66M 41.57M 35.76M 22.17M
Issuance of capital stock 0.34M 0.74M 1.64M 4.51M 34.82M
Depreciation 10.76M 16.25M 20.96M 1.96M 7.79M
Other cashflows from investing activities 0.20M 0.20M 0.01M 0.02M 2.46M
Dividends paid 9.12M 8.60M 2.84M 7.60M 6.35M
Change to inventory -2.21M 1.84M -5.21M 2.04M -4.46M
Change to account receivables -18.72M -6.15M 6.73M -0.50M -7.63M
Other cashflows from financing activities 9.16M -3.89M 78.48M -3.58M 23.93M
Change to netincome 23.35M 15.76M 16.60M 10.85M 8.91M
Capital expenditures 0.61M 5.53M 4.61M 4.16M 2.93M
Change in working capital -14.73M 4.84M 7.45M -2.26M -10.04M
Stock based compensation 0.09M 2.25M 1.37M 1.82M 1.79M
Other non cash items 23.91M 3.62M 2.65M 5.43M 4.28M
Free cash flow 20.36M 33.13M 36.95M 31.60M 19.24M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(GBX)
Price
(GBX)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
HLN
Haleon PLC		 -4.20
1.10%		 376.00 20.24 18.94 2.95 2.02 3.68 14.19
HIK
Hikma Pharmaceuticals PLC		 4.00
0.24%		 1704.00 9.73 9.03 0.85 1.45 1.53 6.07
HCM
HUTCHMED China Ltd		 -2.00
0.95%		 208.00 5.38 19.30 3.37 2.02 2.25 2.40
AGY
Allergy Therapeutics		 -
-%		 4.25 - 106.38 11.72 159.47 12.12 -4.15

Profile*

Alliance Pharma plc

Alliance Pharma plc operates as a pharmaceutical company in Europe, the Middle East, Africa, the Asia Pacific, China, and the Americas. The company acquires, markets, and distributes consumer healthcare and prescription medicine products. The company also offers medicines, medical devices, food supplements, and cosmetics. It provides its products under the Aloclair, Anbesol, Asthon and Parsons, Forceval, Hydromol, Kelo-cote, Macushield, Vamousse, Nizoral, and Amberen brand names. Alliance Pharma plc was incorporated in 1996 and is headquartered in Chippenham, the United Kingdom.

Avonbridge House, Chippenham, United Kingdom, SN15 2BB

44 12 4946 6966

https://www.alliancepharmaceuticals.com

285

Name Title Year Born
Mr. Andrew Timothy Franklin Interim CEO, CFO & Exec. Director 1966
Mr. Peter Jonathan Butterfield CEO & Exec. Director (Leave of Absence) 1976
Mr. Stephen Kidner Chief Scientific Affairs & Operations Officer NA
Ms. Cora Maeve McCallum C.F.A. Head of Investor Relations & Corp. Communications NA
Mr. Alex Duggan Chief Commercial & Corp. Devel. Officer NA
Ms. Janice Timberlake Chief People & Infrastructure Officer NA
Mr. Steve Lobb Head of Hydromol NA
Mr. David Hope Head of Secondary Care NA
Mr. Rajiv Ghidiyal Head of APAC, EMEA & Americas NA
Mr. Karim Husny Head of International NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…